**Terbutaline**

A clidinium bromide

Formoterol

Y

Budesonide /

formoterol

formoterol

salmeterol

Fluticasone Proprionate

Ciclesonide

Budesonide

Olodaterol (LABA) /

Fenoterol

Maximum doses apply – see BNF

Cost based on 100 actuations of 200 micrograms

Spacer compatibility*: o MDI with mouthpiece shape round (not compatible with Volumatic TM spacer device)

Registered Address

Mechanism of action:

- Anti-inflammatory effect on bronchial mucosa
- Improvement in lung function has been shown to improve symptoms
- LABA is preferred rather than inhaled anticholinergics for persistent asthma (≥ Step 3)
- In people with confirmed diagnosis of COPD (and no overlap with asthma) a LABA can be used with no increase in the risk of exacerbations
- No inhaler containing only ICS is necessary
- Symptomatic treatment of persistent asthma (≥ Step 3) with a LABA is preferred
- In certain cases, regular preventative anti-inflammatories (ICS) may require more regular use of SABA, as using prior to movement/exercise may be necessary.
- LABAs should be used cautiously with drugs that increase the risk of prolongation of the QTc interval
- With most LABAs, side effects are relatively common, which may in the long term be associated with dental caries
- Abdominal pain, vomiting, nausea, cough, bronchospasm, headache, dyspepsia and dysgeusia
- Headache, cough, dry mouth and constipation. An increased incidence of cardiovascular and respiratory side effects has been noted
- Headache, pharyngitis and sinusitis
- Tachycardia, fine tremor (particularly in hands), muscle cramps and hypokalaemia
- In studies with indacaterol, upper respiratory tract infections, nasopharyngitis, sinusitis and urinary tract infections were reported
- In studies with olodaterol, upper respiratory tract infections, pharyngitis and urinary tract infections were reported
- Food and Pharmaceutical Agency on behalf of the European Union
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Veterinary Use (CVM)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)